Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$125.72 USD

125.72
1,310,375

-0.05 (-0.04%)

Updated Jul 22, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Elanco (ELAN) Stock Declines After Sale of Aqua Business

by Zacks Equity Research

Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer

by Zacks Equity Research

Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?

by Kinjel Shah

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

Sundeep Ganoria headshot

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

by Sundeep Ganoria

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.

Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as Innovation, M&A Pick Up

by Kinjel Shah

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.

Merck (MRK) Stock Moves 0.28%: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Merck (MRK) stood at $128.12, denoting a +0.28% change from the preceding trading day.

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

by Zacks Equity Research

Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.

The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction

by Zacks Equity Research

are included in this Analyst Blog Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction

Santanu Roy headshot

Top Research Reports for Exxon Mobil, Merck & Qualcomm

by Santanu Roy

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) and QUALCOMM Incorporated (QCOM), as well as two micro-cap stocks Armanino Foods of Distinction, Inc. (AMNF) and AMCON Distributing Company (DIT).

Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

Merck (MRK) reachead $126.04 at the closing of the latest trading day, reflecting a +0.21% change compared to its last close.

Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence

by Zacks Equity Research

Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche

by Zacks Equity Research

Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

by Kinjel Shah

Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

by Zacks Equity Research

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

by Zacks Equity Research

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use

by Zacks Equity Research

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.

Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe

by Zacks Equity Research

Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.

Kinjel Shah headshot

Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

by Kinjel Shah

FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence

by Zacks Equity Research

AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

by Zacks Equity Research

Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.